Gain Therapeutics, Inc.

Ticker GANX

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

11-50 Employees
Based in Bethesda, Maryland

Gain Therapeutics, Inc. is a biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287, in development for the treatment of GBA1 Parkinson’s disease, has completed IND-enabling GLP toxicology studies. Clinical evaluation of GT-02287 is expected to begin this year.

Visit website

REPORT RATINGS

5.0 / 5.0 (8)

Gain Therapeutics, Inc. reports have an aggregate usefulness score of 5.0 based on 8 reviews.

Gain Therapeutics, Inc.